BioSpace News Archive

Chemomab Therapeutics, Ltd. today announced financial and operating results for the full year and fourth quarter ended December 31, 2023, and provided a corporate update.

Antibe Therapeutics Inc. is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced the publication of a new multi-center performance study of its DecisionDx-SCC risk stratification test.

3T Biosciences today announced that it has entered into multiple additional collaborations with leading academic centers and principal investigators to further fuel 3T’s best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) pHLA target discovery platform.

RAPT Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2023.

BriaCell Therapeutics Corp. announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.

Lipocine Inc. today announced financial results for the year ended December 31, 2023 and provided a corporate update.

Commits to reducing Scope 1 and 2 greenhouse gas emissions by 42% from its 2022 baseline by 2030, with commitment to ensuring 70% of supplier emissions have science-based targets by end of fiscal 2028.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences.

Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, reported preliminary, unaudited financial results for the fourth quarter of 2023.